Circassia Pharmaceuticals PLC (CIR) Stock Rating Reaffirmed by Numis Securities Ltd
Circassia Pharmaceuticals PLC (LON:CIR)‘s stock had its “buy” rating restated by stock analysts at Numis Securities Ltd in a report issued on Tuesday. They currently have a GBX 150 ($1.96) price objective on the biopharmaceutical company’s stock. Numis Securities Ltd’s price target points to a potential upside of 60.43% from the company’s current price.
CIR has been the topic of a number of other reports. Stifel Nicolaus cut Circassia Pharmaceuticals PLC to a “hold” rating in a report on Tuesday, June 21st. Royal Bank Of Canada lowered Circassia Pharmaceuticals PLC to a “sector performer” rating and cut their target price for the company from GBX 430 ($5.61) to GBX 105 ($1.37) in a research report on Tuesday, June 21st. Peel Hunt reissued an “under review” rating on shares of Circassia Pharmaceuticals PLC in a research report on Monday, June 20th. JPMorgan Chase & Co. cut their target price on Circassia Pharmaceuticals PLC from GBX 410 ($5.35) to GBX 170 ($2.22) and set an “overweight” rating on the stock in a research report on Tuesday, June 21st. Finally, Barclays PLC began coverage on Circassia Pharmaceuticals PLC in a research report on Tuesday, June 21st. They issued an “overweight” rating and a GBX 170 ($2.22) target price on the stock. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Circassia Pharmaceuticals PLC presently has a consensus rating of “Buy” and a consensus price target of GBX 183.33 ($2.39).
Shares of Circassia Pharmaceuticals PLC (LON:CIR) opened at 93.50 on Tuesday. The stock has a 50 day moving average price of GBX 94.79 and a 200-day moving average price of GBX 179.06. The firm’s market cap is GBX 266.37 billion. Circassia Pharmaceuticals PLC has a 52-week low of GBX 81.05 and a 52-week high of GBX 322.90.
About Circassia Pharmaceuticals PLC
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.